- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00365417
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
A Phase II Clinical Trial of Bevacizumab Beginning Concurrently With a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy Followed by Postoperative Bevacizumab Alone for Women With Locally Advanced Breast Cancer
Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy drugs kill cancer cells more directly. This study will evaluate:
- How bevacizumab, given with chemotherapy before surgery, and then bevacizumab given alone after surgery, will affect locally advanced breast tumors
- Side effects from adding bevacizumab to chemotherapy
- Whether adding bevacizumab to chemotherapy for breast cancer will affect the heart
- If receiving bevacizumab will have any effect on how patients recover from surgery
- Side effects of the combinations of drugs used in this study
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- NSABP Foundation, Inc.
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must be female.
- The patient must be greater than/equal to 18 years old
- The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy.
- Patients must have clinical Stage IIIA, IIIB, or IIIC disease (American Joint Committee on Cancer [AJCC] staging criteria) with a primary breast tumor that is greater than/equal to 2.0 cm measured by clinical exam, unless the patient has inflammatory breast carcinoma, in which case measurable disease is not required.
- Patients must have the ability to swallow oral medication.
- The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1.
At the time of study entry, blood counts must meet the following criteria:
- Absolute neutrophil count (ANC) must be greater than/equal to 1200/mm3.
- Platelet count must be greater than/equal to 100,000/mm^3.
- Hemoglobin must be greater than/equal to 10 g/dL.
The following criteria for evidence of adequate hepatic function must be met:
- total bilirubin must be less than/equal to upper limit of normal (ULN) for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and
- alkaline phosphatase must be less than 2.5 x ULN for the lab; and
- aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab.
- Alkaline phosphatase and AST may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than/equal to 2.5 x ULN, then the AST must be less than/equal to the ULN. If the AST is greater than the ULN but less than/equal to 1.5 x ULN, then the alkaline phosphatase must be less than/equal to ULN.
- Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or positron emission tomography (PET) scan does not demonstrate metastatic disease. Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy.
- Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], MRI, or PET scan) does not demonstrate metastatic disease and adequate hepatic function.
The following criteria for evidence of adequate renal function must be met:
- Serum creatinine less than/equal to ULN for the lab.
- Calculated creatinine clearance must be greater than 50 mL/min.
- Urine protein/creatinine (UPC) ratio must be less than 1.0.
- Patients must have their left ventricular ejection fraction (LVEF) assessed by multigated acquisition (MUGA) scan or echocardiogram within 3 months prior to study entry. The LVEF must be greater than/equal to the lower limit of normal (LLN) for the cardiac imaging facility performing the MUGA scan or echocardiogram. Note: If the cardiac imaging facility cannot provide a LLN, use 50% as the LLN value.
Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if bevacizumab therapy can be continued following doxorubicin and cyclophosphamide (AC) and postoperatively, it is critical that this baseline study be an accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 65%, the MUGA scan or echocardiogram must be repeated prior to study entry. The lower of the two LVEF values should be used as the baseline LVEF.
- Patients must have an electrocardiogram (EKG) within 3 months prior to study entry.
Exclusion Criteria:
- Tumor determined to be strongly HER2-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (positive for gene amplification).
- Excisional biopsy for this primary tumor.
- Synchronous bilateral invasive breast cancer.
- Surgical axillary staging procedure prior to study entry (Exceptions: 1) fine needle aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not recommended, a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted.)
History of any of the following cancers:
- Ipsilateral breast cancer: invasive, ductal carcinoma in situ (DCIS) treated with any therapy other than excision
- Contralateral breast cancer: invasive within the past 5 years (Patients with history of DCIS or synchronous DCIS are eligible)
- History of non-breast malignancies within the 5 years prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
- Prior therapy with anthracyclines, taxanes, capecitabine, or bevacizumab for any malignancy.
- Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to study entry. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before study entry. In such a case, hormonal therapy must stop at or before study entry and be re-started, if indicated, following chemotherapy.
Any of the following cardiac conditions:
- angina pectoris that requires the use of anti-anginal medication;
- history of documented congestive heart failure;
- serious cardiac arrhythmia requiring medication;
- severe conduction abnormality;
- valvular disease with documented cardiac function compromise; or
- uncontrolled hypertension defined as blood pressure greater than 150/90 on antihypertensive therapy. (Patients with hypertension that is well controlled on medication are eligible.)
- History of myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function.
- History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).
- History of other arterial thrombotic event within 12 months before study entry.
- Symptomatic peripheral vascular disease.
- Any significant bleeding within 6 months before study entry.
- Serious or non-healing wound, skin ulcers, or bone fracture.
- Gastroduodenal ulcer(s) determined by endoscopy to be active.
Invasive procedures defined as follows:
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy. (Note: Placement of a vascular access device is not considered a major surgical procedure.)
- Anticipation of need for major surgical procedures (other than the required breast surgery) during the course of the study.
- Known bleeding diathesis or coagulopathy. (Patients on warfarin with an in-range international normalized ratio [INR] [usually between 2 and 3] are eligible.)
- Other nonmalignant systemic disease (cardiovascular, renal, hepatic, diabetes, etc.) that would preclude the patient from receiving study treatment or would prevent required follow-up.
- Sensory/motor neuropathy greater than/equal to grade 2, as defined by the NCI's Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0).
- Conditions that would prohibit administration of corticosteroids.
- History of hypersensitivity reaction to drugs formulated with polysorbate 80.
- Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention. Patients are eligible only if these medications are discontinued prior to study entry.
- Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. These patients are eligible if this therapy is discontinued prior to study entry. (Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy and for at least 3 months after completion of bevacizumab.)
- Pregnancy or lactation at the time of study entry.
- Use of any investigational agent within 4 weeks prior to enrollment in the study.
- Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Doxorubicin+Cyclophosphamide+Bevacizumab
|
15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
Andere namen:
60 mg/m^2 IV every 21 days x 4 cycles
600 mg/m^2 IV every 21 days x 4 cycles
Following clinical response assessment, 650 mg/m^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
Andere namen:
Following clinical response assessment, 75 mg/m^2 IV every 21 days x 4 cycles
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Pathologic Complete Response (pCR) in the Breast
Tijdsspanne: Approximately 7 months
|
Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen
|
Approximately 7 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
pCR in the Breast and Nodes
Tijdsspanne: Approximately 7 months
|
Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel nodes
|
Approximately 7 months
|
Clinical Response Rate (cRR) of the Sequential Regimen
Tijdsspanne: Approximately 6 months
|
Clinical tumor measurements were required before study entry & before cycle 5 of chemotherapy (between AC & TX).
Final tumor measurements were obtained 4-5 weeks after the last dose of chemotherapy.
Clinical tumor assessments by physical examination were recommended before each chemotherapy cycle.
The criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee(RECIST) were used to define clinical response status.
CR was defined as the disappearance of all lesions with no evidence of PD.
PR was defined as at least 30% decrease in the sum of the longest diameter of target lesions, using as reference the baseline sum longest diameter and/or the persistence of greater than or equal to 1 nontarget lesion without worsening of any other clinical manifestations of disease.
PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions, or unequivocal progression of existing lesions.
|
Approximately 6 months
|
Reported Adverse Events
Tijdsspanne: Approximately 14 months
|
Number of Adverse Events
|
Approximately 14 months
|
Cardiac Events
Tijdsspanne: Assessments throughout; up to 18 months following study entry
|
Events: Congestive Heart Failure; Cardiac Death
|
Assessments throughout; up to 18 months following study entry
|
Progression-free Survival
Tijdsspanne: 2 years
|
Percentage of patients free from disease progression.
Progression is determined using international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.
At least a 20% increase in the sum of the longest diameter of the target lesions.
Other manifestations of progressive disease would also be classified as disease progression, eg., appearance of one or more new lesions in the breast, regional lymph nodes or distant sites, unequivocal progression of existing non-target lesions, and appearance of inflammatory carcinoma on clinical exam.
|
2 years
|
Overall Survival
Tijdsspanne: 2 years
|
Percentage of patients alive.
|
2 years
|
Number of Patients With at Least One Surgical Complications (Wound Dehiscence, Infection, Seroma, or Hematoma).
Tijdsspanne: Two (2) years
|
Number of patients with at least one surgical complications (wound dehiscence, infection, seroma, or hematoma)
|
Two (2) years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Huidziektes
- Neoplasmata
- Neoplasmata per site
- Borst ziekten
- Borstneoplasmata
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antireumatische middelen
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Antineoplastische middelen, alkylering
- Alkyleringsmiddelen
- Myeloablatieve agonisten
- Topoisomerase II-remmers
- Topoisomeraseremmers
- Antineoplastische middelen, immunologisch
- Angiogenese-remmers
- Angiogenese modulerende middelen
- Groei stoffen
- Groeiremmers
- Antibiotica, antineoplastiek
- Docetaxel
- Cyclofosfamide
- Capecitabine
- Bevacizumab
- Doxorubicine
Andere studie-ID-nummers
- NSABP FB-4
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Borstkanker
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
Klinische onderzoeken op Bevacizumab
-
National Cancer Institute (NCI)Actief, niet wervendRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Ovarieel heldercellig cystadenocarcinoom | Ovarieel endometrioïde adenocarcinoom | Ovarieel sereus cystadenocarcinoom | Endometrium Clear Cell Adenocarcinoom | Endometrium sereus adenocarcinoom en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)VoltooidCervicaal adenocarcinoom | Cervicaal adenosquameus carcinoom | Cervicaal plaveiselcelcarcinoom, niet anders gespecificeerd | Stadium IVA Baarmoederhalskanker AJCC v6 en v7 | Recidiverend cervicaal carcinoom | Stadium IV Baarmoederhalskanker AJCC v6 en v7 | Stadium IVB Baarmoederhalskanker AJCC...Verenigde Staten
-
National Cancer Institute (NCI)NRG OncologyVoltooidBevacizumab met of zonder trebananib bij de behandeling van patiënten met terugkerende hersentumorenGlioblastoom | Gliosarcoom | Recidiverend glioblastoom | Oligodendroglioom | Gigantisch celglioblastoom | Terugkerend hersenneoplasmaVerenigde Staten, Canada
-
M.D. Anderson Cancer CenterWervingStadium IB Hepatocellulair carcinoom AJCC v8 | Stadium II hepatocellulair carcinoom AJCC v8 | Resectabel hepatocellulair carcinoom | Stadium I hepatocellulair carcinoom AJCC v8 | Stadium IA Hepatocellulair carcinoom AJCC v8Verenigde Staten
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WervingRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Ovarieel endometrioïde adenocarcinoom | Ovarieel heldercellig adenocarcinoom | Eileider Clear Cell Adenocarcinoom | Endometrioïde adenocarcinoom van de eileider | Eileider Sereus Adenocarcinoom en andere voorwaardenVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendOvarieel endometrioïde adenocarcinoom | Primair peritoneaal hooggradig sereus adenocarcinoom | Endometrioïde adenocarcinoom van de eileider | Platina-resistent eileidercarcinoom | Platina-resistent primair peritoneaal carcinoom | Hoogwaardig sereus adenocarcinoom van de eierstokken | Platina-resistent... en andere voorwaardenVerenigde Staten, Canada
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsVoltooidRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Platina-resistent eileidercarcinoom | Platina-resistent primair peritoneaal carcinoom | Platina-resistent ovariumcarcinoom | Refractair ovariumcarcinoom | Refractair eileidercarcinoom | Refractair...Verenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendStadium IV huidmelanoom AJCC v6 en v7 | Stadium IIIC Cutaan Melanoom AJCC v7 | Inoperabel melanoomVerenigde Staten
-
National Cancer Institute (NCI)Actief, niet wervendRecidiverend glioblastoomVerenigde Staten
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsWervingRecidiverend eileidercarcinoom | Recidiverend ovariumcarcinoom | Recidiverend primair peritoneaal carcinoom | Recidiverend endometrium sereus adenocarcinoom | Ovarieel heldercellig adenocarcinoom | Recidiverend platinaresistent ovariumcarcinoom | Platinagevoelig ovariumcarcinoom | Recidiverend endometrioïde... en andere voorwaardenVerenigde Staten